Chenchen Tang

Chenchen Tang

Auto-generated profile, based on publicly available information

Chenchen Tang

Biobank, Jilin Cancer Hospital, Changchun 130012, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2021 in Science China Life Sciences
Verified
Journal Article
Closed access
PDF file
CZChun Zhang
Chun Zhang
QLQi Li
Qi Li
LZLa Zhu
La Zhu
WHWangchao He
Wangchao He
CYConghui Yang
Conghui Yang
SLShaojun Liu
Shaojun Liu

8 November 2021 in Science China Life Sciences
Verified
Journal Article
Closed access
PDF file
DGDingbin Gong
Dingbin Gong
MTMin Tao
Min Tao
LXLihui Xu
Lihui Xu
FHFangzhou Hu
Fangzhou Hu
ZWZehong Wei
Zehong Wei
SLShaojun Liu
Shaojun Liu

16 January 2025 in Cancer Science
Verified
Journal Article
Open access
HLHui Li
Hui Li
CTChenchen Tang
Chenchen Tang
PZPeiyan Zhao
Peiyan Zhao
RZRui Zhong
Rui Zhong
YLYuanhua Lu
Yuanhua Lu
YLYing Liu
Ying Liu
There is an urgent need to develop new targeted treatment agents for small cell lung cancer (SCLC). Tinengotinib (TT‐00420) is a novel, multi‐targeted, and spectrally selective small‐molecule kinase inhibitor that has shown significant inhibitory effects on certain solid tumors in preclinical studies. However, its role and mechanism of action in SCLC remain unclear. In this study, we demonstrated that tinengotinib effectively inhibited SCLC cell proliferation, especially highly expressing NeuroD1 (SCLC‐N), in the SCLC cell line‐derived xenograft (CDX) model and the malignant pleural effusion cell model of patients with SCLC. When combined with etoposide/cisplatin, it synergistically inhibited SCLC growth. Tinengotinib regulates proliferation, apoptosis, migration, cell cycle and angiogenesis in SCLC cells. Mechanistic studies revealed that c‐Myc expression may be a key factor influencing the effect of tinengotinib in SCLC‐N. This study provides reliable preclinical data and a new direction for tinengotinib as a promising therapy for SCLC, either alone or in combination with chemotherapy.

31 October 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
SLShaowei Lan
Shaowei Lan
LMLixia Ma
Lixia Ma
CTChenchen Tang
Chenchen Tang
XWXinyue Wang
Xinyue Wang
YLYing Liu
Ying Liu
YCYing Cheng
Ying Cheng
Conventional three-dimensional (3D) organoid models are limited by high cost, technical complexity, and poor replication of tumor-immune interactions. To address these limitations, we developed two novel 2.5D systems from malignant pleural effusion (MPE) of patients with lung adenocarcinoma. The first uses MPE-derived adherent cells to create matrix-free niches, while the second combines MPE supernatant with DMEM-F12 and 10-30 % fetal bovine serum, with or without agarose, to form a thermoresponsive matrix that mimics dynamic tumor microenvironments. Autologous MPE supernatants were used to preserve native cytokines and extracellular matrix components. Genomic and immune microenvironment analyses demonstrated over 90 % concordance between 2.5D organoids and parental tumors, which aligned with the standards reported for existing 3D tumor-organoid cultures. The 2.5D organoids retained key functional characteristics, including mucus secretion, phenotypic plasticity, and angiogenesis. Organoid-based high-throughput screening enabled identification of candidate therapeutics, and drug sensitivity assays correlated strongly with patient outcomes, underscoring their utility for personalized medicine. The matrix-free design facilitated rapid organoid generation (3-10 days) and reduced costs by approximately 90 % relative to conventional 3D methods. These 2.5D models provide a clinically translatable platform that replicates tumor heterogeneity while overcoming cost and technical barriers, offering a promising tool for precision pharmacology and oncology.